CA2511726A1 - Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques - Google Patents

Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques Download PDF

Info

Publication number
CA2511726A1
CA2511726A1 CA002511726A CA2511726A CA2511726A1 CA 2511726 A1 CA2511726 A1 CA 2511726A1 CA 002511726 A CA002511726 A CA 002511726A CA 2511726 A CA2511726 A CA 2511726A CA 2511726 A1 CA2511726 A1 CA 2511726A1
Authority
CA
Canada
Prior art keywords
compound
formula
group
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002511726A
Other languages
English (en)
Inventor
Anita Mehta
Sanjay Kumar Srivastava
Jang Bahadur Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CA2511726A1 publication Critical patent/CA2511726A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des dérivés d'azabicyclo[3.1.0] 3,6-disubstitués. Les composés de la présente invention peuvent être utilisés en tant qu'antagonistes des récepteurs muscariniques, notamment pour le traitement de diverses maladies des systèmes respiratoire, urinaire et gastrointestinal, maladies dont la médiation est assurée par les récepteurs muscariniques. L'invention se rapporte également à un procédé de préparation de ces composés, à des compositions pharmaceutiques contenant ces composés et à des méthodes de traitement des maladies dont la médiation est assurée par les récepteurs muscariniques.
CA002511726A 2002-12-23 2002-12-23 Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques Abandoned CA2511726A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/005589 WO2004056810A1 (fr) 2002-12-23 2002-12-23 Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques

Publications (1)

Publication Number Publication Date
CA2511726A1 true CA2511726A1 (fr) 2004-07-08

Family

ID=32676694

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002511726A Abandoned CA2511726A1 (fr) 2002-12-23 2002-12-23 Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques

Country Status (4)

Country Link
EP (1) EP1590345A1 (fr)
AU (1) AU2002356369A1 (fr)
CA (1) CA2511726A1 (fr)
WO (1) WO2004056810A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546099B1 (fr) 2002-07-08 2008-12-31 Ranbaxy Laboratories Limited Derives d'azabicyclo 3.1.0 hexanes 3,6-disubstitues utiles comme antagonistes des recepteurs muscariniques
WO2004089898A1 (fr) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
ATE419246T1 (de) * 2004-06-16 2009-01-15 Ranbaxy Lab Ltd Als antagonisten des muscarinrezeptors geeignete xanthinderivate
EP1934184A1 (fr) 2005-10-05 2008-06-25 Ranbaxy Laboratories, Ltd. Dérivés de 3 -azabicyclooctane en tant qu antagonistes de récepteurs muscariniques
WO2007077510A2 (fr) 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Antagonistes des récepteurs muscariniques
EP1968980A1 (fr) 2005-12-30 2008-09-17 Ranbaxy Laboratories, Ltd. Antagonistes des récepteurs muscariniques
WO2008133900A1 (fr) 2007-04-24 2008-11-06 Theravance, Inc. Composés d'ammonium quaternaire utiles en tant qu'antagonistes des récepteurs muscariniques
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2012042539A2 (fr) 2010-09-28 2012-04-05 Panacea Biotec Ltd Nouveaux composés bicycliques
JP2022534426A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8721978A0 (it) * 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.

Also Published As

Publication number Publication date
WO2004056810A1 (fr) 2004-07-08
AU2002356369A1 (en) 2004-07-14
EP1590345A1 (fr) 2005-11-02

Similar Documents

Publication Publication Date Title
US7288562B2 (en) Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
US7399779B2 (en) 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
US7265147B2 (en) 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7446123B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
US7501443B2 (en) Flavaxate derivatives as muscarinic receptor antagonists
CA2511726A1 (fr) Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques
US20070010568A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7592359B2 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20060281805A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7560479B2 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1545508A1 (fr) Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
KR20060014373A (ko) 무스카린 수용체 길항제로서의 치환된 아자비시클로 헥산유도체

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead